Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Hansa Biopharma Partners with Cradle to Advance AI-Driven Protein Design and Engineering

1 October 2026 · By · Wire by Fusion42

Published

1 October 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

Europe

◆ Source

Read at au.finance.yahoo.com →

◆ Verified

Fusion42 · 1 October 2026 · Fusion42 review

Hansa Biopharma has partnered with Cradle to use its AI-driven protein design and engineering platform to accelerate the discovery and development of novel immunomodulatory therapies for autoimmune diseases. The collaboration aims to shorten development timelines and improve the success rate of therapeutic candidates.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

AI-driven protein design is becoming a core tool in autoimmune drug discovery. If you are in therapeutic development, expect faster design cycles and sharper candidate optimisation to reshape your R&D timelines.

◆ Coverage

1 source · 1 Oct 2026

◆ Related on Wire

◆ Topics

Biotechai-drivenprotein-designdrug-discoveryautoimmune-diseasepartnership